Effects of Neuro-myo-electrical Stimulation on Insulin Sensitivity in Patients With Type 2 Diabetes

Type 2 diabetes is a major public health problem because of its increasing prevalence and morbidity and mortality that accompanies it. Therapeutic management of this pathology, lifestyle measures, dietary and physical activity are fundamental. Their observance is unfortunately too often insufficient, leading to a therapeutic climbing with first oral antidiabetic (OAD) then the use of insulin therapy.

Yet there is now ample evidence that physical activity improves glucose control in these patients in particular improving insulin sensitivity after a training period but also after a single session of physical activity.

Neuro-myo-electrical stimulation (NMES) is used in common clinical practice in physical therapy, patients with neurological or after orthopedic surgery in particular. In fact, this method enables improvement of volume and strength, even for denervated muscles. Recent studies have also shown the benefits of NMES in situations of cardiac or respiratory readjustments. In addition, NMES is used by top athletes supplements classical training in order to develop muscle strength or speed recovery.

Investigators propose to test the impact of bilateral quadriceps NMES on insulin sensitivity in type 2 diabetic patients treated with OAD (excluding glitazone). To do this, investigators plan to assess their insulin sensitivity by the reference method of hyperinsulinemic euglycemic clamp before surgery, after a single session of bilateral quadriceps NMES and after a sequence of daily training 6 days a quadriceps NMES bilateral.

Investigators hope to show an improvement in insulin sensitivity by this method, which would constitute an alternative to physical activity in the treatment of diabetes type 2. This procedure would be particularly interesting in diabetic subjects with type 2 counter- indications or an inability to perform a conventional physical activity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Endocrinology Unit and Clinical Research Center Basse Normandie, University Hospital of Caen

Caen, 14000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Men and women 18-75 years of age:
Type 2 diabetes,
in a context of overweight BMI upper than 25 kg / m²,
a glycated hemoglobin included between 6 and 9%,
treated with oral antidiabetic (non glitazone) and / or GLP1 analogs (stable treatment for 3 months).
Patient who signed informed consent.

Exclusion criteria

Type 1 diabetes
Children or adolescents under 18 years.
Patients over 75 years.
Pregnancy.
Patient intense practicing regular physical activity and do not wish to interrupt the time of the study
Patients with painful joint disease of the knee mobilization (osteoarthritis, inflammatory arthritis), any severe neuromuscular disease (diabetic neuropathy with pain, cramps, paresthesia, hypoesthesia, degenerative muscle disease).
Patients with unstable ischemic heart disease or arterial disease severe lower limbs.
Presence of a pacemaker (pacemaker).
Epilepsy
Patients insulin applicants
Treatment with glitazone.
Sepsis or other intercurrent acute disease (heart attack, angina ..).
Patients with skin lesions of any kind (wounds, inflammations, burns, irritations, eczema, etc.) nearby with areas for electrodes NMES
Patients unable to comply with the safety instructions of the NMES device at home
Patient unable to submit to medical monitoring study for geographical, social or psychological.
Patients under guardianship or trusteeship.
Patient included in another biomedical research protocol

Treatment and study plan

acute muscle exercise by NMES

Device

daily workout sequence with NMES in one week

Device

rest situation

Other

Primary outcomes

insulin sensitivity measured by the reference euglycemic hyperinsulinemic clamp technique

Time frame: change over time : baseline, week 1, end of week 2

Sponsors and collaborators

Lead sponsor

University Hospital, Caen

Other

Registry information

Acronym: ELECTRODIAB

Important dates

Study start: 2012
Primary completion: 2013
Study completion: 2014
First posted: Jul 29, 2015
Registry last updated: Apr 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed